Page last updated: 2024-12-11

ci 940

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

leptomycin : A complex, very long chain, polyunsaturated fatty acid whose core structure comprises 8-oxononadeca-2,10,12,16,18-pentaenoic acid having methyl substituents at positions 3, 5, 7, 9, 11 and 15 and a 3,6-dihydropyran-6-one-2-yl group at position 19. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6917907
CHEMBL ID486133
CHEBI ID52646
SCHEMBL ID12361304
MeSH IDM0116469

Synonyms (44)

Synonym
unii-y031i2n1eo
y031i2n1eo ,
pd-114720
ci-940
kos-1688
cl-1957a
2,10,12,16,18-nonadecapentanoic acid, 19-(3,6-dihydro-3-methyl-6-oxo-2h-pyran-2-yl)-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-8-oxo-
antibiotic cl 1957a
2,10,12,16,18-nonadecapentaenoic acid, 19-(3,6-dihydro-3-methyl-6-oxo-2h-pyran-2-yl)-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-8-oxo-
cl 1957a
c33h48o6
nsc 364372
nsc-364372
elactocin
(2e,5s,6r,7s,9r,10e,12e,15r,16z,18e)-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-19-[(2s,3s)-3-methyl-6-oxo-2,3-dihydropyran-2-yl]-8-oxo-nonadeca-2,10,12,16,18-pentaenoic acid
mantuamycin
2,10,12,16,18-nonadecapentaenoic acid, 19-[(2s,3s)-3,6-dihydro-3-methyl-6-oxo-2h-pyran-2-yl]-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-8-oxo-,(2e,5s,6r,7s,9r,10e,12e,15r,16z,18e)-
pd 114720
antibiotic ci 940
LMB ,
ci 940
(2e,10e,12e,16e,18e)-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-19-(3-methyl-6-oxo-2,3-dihydropyran-2-yl)-8-oxo-nonadeca-2,10,12,16,18-pentaenoic acid
(2e,5s,6r,7s,9r,10e,12e,15r,16z,18e)-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-19-[(2s,3s)-3-methyl-6-oxo-3,6-dihydro-2h-pyran-2-yl]-8-oxononadeca-2,10,12,16,18-pentaenoic acid
antibiotic ats 1287b
CHEBI:52646 ,
ats 1287b
antibiotic pd 114720
CHEMBL486133
leptomycin
(2e,5s,6r,7s,9r,10e,12e,15r,16z,18e)-19-((2s,3s)-3,6-dihydro-3-methyl-6-oxo-2h-pyran-2-yl)-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-8-oxo-2,10,12,16,18-nonadecapentaenoic acid
leptomycin b [mi]
(2e,5s,6r,7s,9r,10e,12e,15r,16z,18e)-19-[(2s,3s)-3,6-dihydro-3-methyl-6-oxo-2h-pyran-2-yl]-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-8-oxo-2,10,12,16,18-nonadecapentaenoic acid
SCHEMBL12361304
AKOS030568045
leptomycin b, streptomyces sp. ats1287
HB4219
leptomycin b from streptomyces sp
(2e,5s,6r,7s,9r,10e,12e,15r,16z,18e)-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-19-((2s,3s)-3-methyl-6-oxo-3,6-dihydro-2h-pyran-2-yl)-8-oxononadeca-2,10,12,16,18-pentaenoic acid
Q6528191
bdbm50245464
CS-0012947
HY-16909
EX-A4641
leptomycin b, free acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antifungal agentAn antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce.
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
leptomycinA complex, very long chain, polyunsaturated fatty acid whose core structure comprises 8-oxononadeca-2,10,12,16,18-pentaenoic acid having methyl substituents at positions 3, 5, 7, 9, 11 and 15 and a 3,6-dihydropyran-6-one-2-yl group at position 19.
hydroxy polyunsaturated fatty acidAny polyunsaturated fatty acid carrying one or more hydroxy substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency0.00470.00529.466132.9993AID1347411
Interferon betaHomo sapiens (human)Potency0.00470.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Exportin-1Homo sapiens (human)IC50 (µMol)0.07600.00100.58401.6000AID1469802; AID1656191
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (41)

Processvia Protein(s)Taxonomy
protein export from nucleusExportin-1Homo sapiens (human)
ribosomal subunit export from nucleusExportin-1Homo sapiens (human)
ribosomal large subunit export from nucleusExportin-1Homo sapiens (human)
ribosomal small subunit export from nucleusExportin-1Homo sapiens (human)
mRNA export from nucleusExportin-1Homo sapiens (human)
protein export from nucleusExportin-1Homo sapiens (human)
nucleocytoplasmic transportExportin-1Homo sapiens (human)
regulation of centrosome duplicationExportin-1Homo sapiens (human)
regulation of proteasomal ubiquitin-dependent protein catabolic processExportin-1Homo sapiens (human)
protein localization to nucleusExportin-1Homo sapiens (human)
ribosome biogenesisExportin-1Homo sapiens (human)
regulation of protein export from nucleusExportin-1Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
RNA bindingExportin-1Homo sapiens (human)
nuclear export signal receptor activityExportin-1Homo sapiens (human)
protein bindingExportin-1Homo sapiens (human)
small GTPase bindingExportin-1Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
kinetochoreExportin-1Homo sapiens (human)
nuclear envelopeExportin-1Homo sapiens (human)
annulate lamellaeExportin-1Homo sapiens (human)
nucleoplasmExportin-1Homo sapiens (human)
nucleolusExportin-1Homo sapiens (human)
cytoplasmExportin-1Homo sapiens (human)
cytosolExportin-1Homo sapiens (human)
Cajal bodyExportin-1Homo sapiens (human)
membraneExportin-1Homo sapiens (human)
nuclear membraneExportin-1Homo sapiens (human)
intracellular membrane-bounded organelleExportin-1Homo sapiens (human)
protein-containing complexExportin-1Homo sapiens (human)
ribonucleoprotein complexExportin-1Homo sapiens (human)
nucleusExportin-1Homo sapiens (human)
cytoplasmExportin-1Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID1347414qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1524205Antiviral activity against Influenza A virus (A/WSN/33) infected in MDCK cells assessed as reduction in NS2 protein distribution to cytoplasm at 10 nM measured after 9 hrs post infection by IF-staining based microscopy2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Design, Synthesis, and Biological Evaluation of Itaconic Acid Derivatives as Potential Anti-Influenza Agents.
AID1524204Antiviral activity against Influenza A virus (A/WSN/33) infected in MDCK cells assessed as reduction in NP protein distribution to cytoplasm at 10 nM measured after 9 hrs post infection by IF-staining based microscopy2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Design, Synthesis, and Biological Evaluation of Itaconic Acid Derivatives as Potential Anti-Influenza Agents.
AID1656196Inhibition of immobilized HsCRM1-HsRanGTP-HsSPN binding to C-terminal His6-tagged and MBP-fused full length human CRM1 expressed in Escherichia coli SG13009 at 20 nmol incubated for 20 mins by pull-down assay2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Characterization of Inhibition Reveals Distinctive Properties for Human and
AID503141Induction of subcellular localization in p27 in african green monkey COS7 cells at 10 ng/ml after 6 hrs by immunofluorescence assay2007Nature chemical biology, Sep, Volume: 3, Issue:9
Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
AID582292Inhibition of HIV1 Rev expressed in human HeLa cells co-expressing renilla luciferase reporter gene assessed as inhibition of renilla luciferase expression after 24 hrs2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Heterocyclic compounds that inhibit Rev-RRE function and human immunodeficiency virus type 1 replication.
AID1656197Inhibition of fluorescently labeled PKI phi(0)Leu NES binding to Saccharomyces cerevisiae CRM1 expressed in Escherichia coli BL21 (DE3) at 2 to 2000 nM by fluorescence polarization competition binding assay2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Characterization of Inhibition Reveals Distinctive Properties for Human and
AID344805Inhibition of CRM1-mediated nucleocytoplasmic transport of HIV1 RevM5 mutant in human HeLa cells assessed as HIV1 RevM5-GFP nuclear localization at 25 nM after 2 hrs by fluorescence microscopy2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action.
AID1524214Inhibition of viral protein sub-cellular distribution in Influenza A virus (A/WSN/33) infected in MDCK cells assessed as reduction in PA protein distribution to cytoplasm at 10 nM measured after 9 hrs post infection by IF-staining based microscopy2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Design, Synthesis, and Biological Evaluation of Itaconic Acid Derivatives as Potential Anti-Influenza Agents.
AID1524156Cytotoxicity against MDCK cells assessed as cell death after 72 hrs by MTT assay2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Design, Synthesis, and Biological Evaluation of Itaconic Acid Derivatives as Potential Anti-Influenza Agents.
AID1656200Inhibition of fluorescently labeled PKI phi(0)Leu NES binding to Saccharomyces cerevisiae CRM1 Thr539Cys mutant expressed in Escherichia coli BL21 (DE3) at 2 to 2000 nM by fluorescence polarization competition binding assay2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Characterization of Inhibition Reveals Distinctive Properties for Human and
AID503322Antiproliferative activity against human PC3 cells at 10 ng/ml after 120 hrs by MTT assay relative to DMSO2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID1656192Inhibition of fluorescently labeled PKI phi(0)Leu NES binding to human CRM1 C528S mutant expressed in Escherichia coli BL21 (DE3) at 200 nM by fluorescence polarization competition binding assay2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Characterization of Inhibition Reveals Distinctive Properties for Human and
AID1524206Antiviral activity against Influenza A virus (A/WSN/33) infected in MDCK cells assessed as reduction in PA protein distribution to cytoplasm at 10 nM measured after 9 hrs post infection by IF-staining based microscopy2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Design, Synthesis, and Biological Evaluation of Itaconic Acid Derivatives as Potential Anti-Influenza Agents.
AID1524215Inhibition of viral protein sub-cellular distribution in Influenza A virus (A/WSN/33) infected in MDCK cells assessed as reduction in M1 protein distribution to cytoplasm at 10 nM measured after 9 hrs post infection by IF-staining based microscopy2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Design, Synthesis, and Biological Evaluation of Itaconic Acid Derivatives as Potential Anti-Influenza Agents.
AID344808Inhibition of Rev-BFP/CRM1-EYFP interaction in human HeLa cells assessed as Rev-BFP/CRM1-EYFP nuclear colocalization by fluorescence microscopy2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action.
AID1524207Antiviral activity against Influenza A virus (A/WSN/33) infected in MDCK cells assessed as reduction in M1 protein distribution to cytoplasm at 10 nM measured after 9 hrs post infection by IF-staining based microscopy2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Design, Synthesis, and Biological Evaluation of Itaconic Acid Derivatives as Potential Anti-Influenza Agents.
AID503142Induction of subcellular localization in truncated p27 in african green monkey COS7 cells at 10 ng/ml after 6 hrs by immunofluorescence assay2007Nature chemical biology, Sep, Volume: 3, Issue:9
Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
AID1524157Selectivity ratio of CC50 for MDCK cells to EC50 for Influenza A virus (A/WSN/33)2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Design, Synthesis, and Biological Evaluation of Itaconic Acid Derivatives as Potential Anti-Influenza Agents.
AID344809Inhibition of Rev-BFP/CRM1Cys528Ser-EYFP mutant interaction in human HeLa cells assessed as Rev-BFP/CRM1Cys528Ser-EYFP nuclear colocalization at 25 nM after 2 hrs by fluorescence microscopy2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action.
AID582293Inhibition of HIV1 Rev expressed in human HeLa cells co-expressing firefly luciferase reporter gene assessed as inhibition of firefly luciferase expression after 24 hrs2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Heterocyclic compounds that inhibit Rev-RRE function and human immunodeficiency virus type 1 replication.
AID1524213Inhibition of viral protein sub-cellular distribution in Influenza A virus (A/WSN/33) infected in MDCK cells assessed as reduction in NS2 protein distribution to cytoplasm at 10 nM measured after 9 hrs post infection by IF-staining based microscopy2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Design, Synthesis, and Biological Evaluation of Itaconic Acid Derivatives as Potential Anti-Influenza Agents.
AID1469802Inhibition of CRM1-mediated nucleocytoplasmic transport in human HeLa cells after 90 mins by immunofluorescence assay2017Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3
Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions.
AID1524155Antiviral activity against Influenza A virus (A/WSN/33) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 72 hrs by crystal violet-staining based assay2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Design, Synthesis, and Biological Evaluation of Itaconic Acid Derivatives as Potential Anti-Influenza Agents.
AID1656191Inhibition of fluorescently labeled PKI phi(0)Leu NES binding to human CRM1 expressed in Escherichia coli BL21 (DE3) by fluorescence polarization competition binding assay2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Characterization of Inhibition Reveals Distinctive Properties for Human and
AID1524216Inhibition of CRM1 in MDCK cells infected with Influenza A virus (A/WSN/33) assessed as reduction in CRM1-mediated viral protein nuclear export by measuring reduction in NP protein distribution to cytoplasm at 10 nM measured after 9 hrs post infection by 2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Design, Synthesis, and Biological Evaluation of Itaconic Acid Derivatives as Potential Anti-Influenza Agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (50.00)29.6817
2010's2 (25.00)24.3611
2020's2 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.23 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index37.53 (26.88)
Search Engine Supply Index3.60 (0.95)

This Compound (24.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]